{"id":225153,"date":"2026-02-20T12:31:08","date_gmt":"2026-02-20T09:31:08","guid":{"rendered":"https:\/\/new-inbit.dev-praxis.gr\/?post_type=hta_library&#038;p=225153"},"modified":"2026-02-20T12:31:09","modified_gmt":"2026-02-20T09:31:09","slug":"health-technology-assessment-in-canada-20-years-strong","status":"publish","type":"hta_library","link":"https:\/\/www.inbit.gr\/el\/hta_library\/health-technology-assessment-in-canada-20-years-strong\/","title":{"rendered":"Health Technology Assessment in Canada: 20 Years Strong?"},"content":{"rendered":"\n<p>Introduction<\/p>\n\n\n\n<p>For over 40 years, Canada has had a publicly funded, national&nbsp;health-care system designed to ensure residents receive \u201creasonable&nbsp;access\u201d to \u201cmedically necessary\u201d health-care services,&nbsp;regardless of their ability to pay [1]. However, unlike many of its&nbsp;European counterparts, Canada\u2019s system is a decentralized one,&nbsp;comprised of 13 separate provincial and territorial health insurance&nbsp;plans. Guided by common values (e.g., equity and solidarity)&nbsp;and responsible for meeting basic standards of coverage,&nbsp;these plans determine how best to organize, manage, and deliver&nbsp;health care within their jurisdictions. Decisions regarding which&nbsp;new technologies to include in the basket of publicly funded&nbsp;services, therefore, rest with individual provinces and territories,&nbsp;and the role of the federal government remains primarily limited&nbsp;to premarket approval and, in the case of patented pharmaceuticals,&nbsp;price regulation. It has, however, retained responsibility&nbsp;for providing services to limited populations, such as veterans,&nbsp;the military, first nations, and inmates.&nbsp;Canada\u2019s history in health technology assessment (HTA), a&nbsp;field developed to support purchasing or coverage decisions,&nbsp;reflects the decentralized nature of the country\u2019s health-care&nbsp;system. Its roots predominantly exist at the provincial level, with&nbsp;the establishment of the Conseil d\u2019evaluation des technologies de&nbsp;la sante (CETS) (now called the Agence des technologies et des&nbsp;modes intervention en sante [AETMIS]) in Quebec 20 years ago&nbsp;[2]. At around the same time, a joint committee representing the&nbsp;federal, provincial, and territorial ministries of health identified&nbsp;HTA as one of its key priorities and announced the creation of&nbsp;a national, independent HTA body called the Canadian Coordinating&nbsp;Office of Health Technology Assessment (renamed&nbsp;the Canadian Agency for Drugs and Technologies in Health&nbsp;(CADTH) in 2006). Funded by the provincial, territorial, and&nbsp;federal governments, its mandate is to provide impartial,&nbsp;evidence-based information on the clinical and economic implications&nbsp;of drugs and other health technologies (including devices,&nbsp;procedures, and systems) to the 13 public insurance plans. Since&nbsp;then, HTA has played an increasingly important role in technology&nbsp;coverage policy in Canada.With the demand for assessments&nbsp;exceeding resources available to the national HTA agency and&nbsp;the types of requests broadening to include context specific questions&nbsp;framed from perspectives other than that of society, the past&nbsp;20 years have seen the emergence of local HTA initiatives in&nbsp;hospitals, regional health authorities, and provinces across the&nbsp;country. Now more than ever, decision-makers at all levels of&nbsp;government are investing in \u201cinstitutionalized\u201d HTA, creating a&nbsp;landscape shaped by a combination of ongoing national and&nbsp;local efforts.&nbsp;In this article, the production and use of HTA in health-care&nbsp;decisions in Canada is described in Section I. Current issues in&nbsp;technology assessment are discussed in Section II. Section III&nbsp;represents our personal views on lessons learned from the HTA&nbsp;experience in Canada.<\/p>\n","protected":false},"featured_media":0,"template":"","categories":[21],"tags":[],"class_list":["post-225153","hta_library","type-hta_library","status-publish","hentry","category-review-papers"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.inbit.gr\/el\/wp-json\/wp\/v2\/hta_library\/225153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inbit.gr\/el\/wp-json\/wp\/v2\/hta_library"}],"about":[{"href":"https:\/\/www.inbit.gr\/el\/wp-json\/wp\/v2\/types\/hta_library"}],"wp:attachment":[{"href":"https:\/\/www.inbit.gr\/el\/wp-json\/wp\/v2\/media?parent=225153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.inbit.gr\/el\/wp-json\/wp\/v2\/categories?post=225153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.inbit.gr\/el\/wp-json\/wp\/v2\/tags?post=225153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}